{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:16:10Z","timestamp":1772151370253,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12328-025-02265-1","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:35:04Z","timestamp":1765805704000},"page":"291-297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Durable disease control in unresectable hepatocellular carcinoma with atezolizumab plus half-dose bevacizumab: pathological complete response of peritoneal metastasis"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9143-256X","authenticated-orcid":false,"given":"Haruki","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Maehira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhito","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeru","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Kaida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsushi","family":"Takebayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaji","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"2","key":"2265_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","volume":"156","author":"L Kulik","year":"2019","unstructured":"Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477-491.e1.","journal-title":"Gastroenterology"},{"issue":"1","key":"2265_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"2265_CR3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma (IMbrave150): updated efficacy and safety data. Lancet Oncol. 2020;21(6):808\u201320.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2265_CR4","first-page":"180","volume":"14","author":"J Yang","year":"2024","unstructured":"Yang J, Choi WM, Kim HD, et al. Higher risk of proteinuria with atezolizumab plus bevacizumab than lenvatinib in first-line systemic treatment for hepatocellular carcinoma. Liver Cancer. 2024;14(2):180\u201392.","journal-title":"Liver Cancer"},{"issue":"10","key":"2265_CR5","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.3390\/cancers15102853","volume":"15","author":"K Mizuno","year":"2023","unstructured":"Mizuno K, Imai N, Yamamoto T, et al. Pretreatment proteinuria predicts the prognosis of patients receiving systemic therapy for unresectable hepatocellular carcinoma. Cancers (Basel). 2023;15(10):2853.","journal-title":"Cancers (Basel)"},{"key":"2265_CR6","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","volume":"7","author":"JJ Wallin","year":"2016","unstructured":"Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624.","journal-title":"Nat Commun"},{"issue":"4","key":"2265_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000535501","volume":"13","author":"M Kudo","year":"2023","unstructured":"Kudo M, Tsuchiya K, Shao YY, et al. Impact of bevacizumab being skipped due to adverse events of special interest for bevacizumab in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: an exploratory analysis of the phase III IMbrave150 study. Liver Cancer. 2023;13(4):401\u201312.","journal-title":"Liver Cancer"},{"issue":"2","key":"2265_CR8","first-page":"e1464","volume":"5","author":"A Hiraoka","year":"2022","unstructured":"Hiraoka A, Kumada T, Tada T, et al. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: early clinical experience. Cancer Rep. 2022;5(2):e1464.","journal-title":"Cancer Rep"},{"issue":"3","key":"2265_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/hepr.13732","volume":"52","author":"M Chuma","year":"2022","unstructured":"Chuma M, Uojima H, Hattori N, et al. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: a multicenter analysis. Hepatol Res. 2022;52(3):269\u201380.","journal-title":"Hepatol Res"},{"issue":"3","key":"2265_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000528145","volume":"12","author":"Y Ando","year":"2022","unstructured":"Ando Y, Kawaoka T, Kosaka M, et al. Risk factors for early onset of proteinuria in patients receiving atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Liver Cancer. 2022;12(3):251\u201361.","journal-title":"Liver Cancer"},{"key":"2265_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41698-025-00908-7","volume":"9","author":"D Ball","year":"2025","unstructured":"Ball D, Nault JC, Vithayathil M, et al. Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma. NPJ Precis Oncol. 2025;9:129.","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"2265_CR12","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s00535-025-02233-z","volume":"60","author":"T Aoki","year":"2025","unstructured":"Aoki T, Kudo M, Nishida N, et al. Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study. J Gastroenterol. 2025;60(6):738\u201353.","journal-title":"J Gastroenterol"},{"issue":"1","key":"2265_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11060-020-03404-z","volume":"147","author":"T Carvalho","year":"2020","unstructured":"Carvalho T, Lopes RG, Linhares P, et al. Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients. J Neurooncol. 2020;147(1):109\u201316.","journal-title":"J Neurooncol"},{"issue":"1","key":"2265_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21(1):60\u20135.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2265_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1757-2215-5-17","volume":"5","author":"C Defferrari","year":"2012","unstructured":"Defferrari C, Campora S, D\u2019Amico M, et al. A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer. J Ovarian Res. 2012;5(1):17.","journal-title":"J Ovarian Res"},{"issue":"4","key":"2265_CR16","first-page":"1928","volume":"25","author":"F Kose","year":"2020","unstructured":"Kose F, Alemdaroglu S, Mertsoylu H, et al. Half-dose bevacizumab experience in relapsed ovarian cancer patients in Turkey due to formal regulations: similar effectiveness with lower rate of hypertension. J BUON. 2020;25(4):1928\u201334.","journal-title":"J BUON"},{"key":"2265_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106239","volume":"198","author":"Y Chen","year":"2020","unstructured":"Chen Y, Guo L, Li X, et al. Reduced-dose bevacizumab vs. standard-dose bevacizumab in recurrent high-grade glioma: which one is better? A meta-analysis. Clin Neurol Neurosurg. 2020;198:106239.","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"2265_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139\u201348.","journal-title":"J Exp Med"},{"issue":"3","key":"2265_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162\u201374.","journal-title":"Nat Rev Immunol"},{"issue":"5706","key":"2265_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58\u201362.","journal-title":"Science"},{"issue":"10","key":"2265_CR21","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","volume":"73","author":"Y Huang","year":"2013","unstructured":"Huang Y, Goel S, Duda DG, et al. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73(10):2943\u20138.","journal-title":"Cancer Res"},{"key":"2265_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.719836","volume":"11","author":"T Yang","year":"2021","unstructured":"Yang T, Xiao H, Liu X, et al. Vascular normalization: a new window opened for cancer therapies. Front Oncol. 2021;11:719836.","journal-title":"Front Oncol"},{"issue":"43","key":"2265_CR23","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA. 2012;109(43):17561\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2265_CR24","doi-asserted-by":"publisher","first-page":"943","DOI":"10.21873\/anticanres.16239","volume":"43","author":"T Miyata","year":"2023","unstructured":"Miyata T, Sugi K, Horino T, et al. Conversion surgery after atezolizumab plus bevacizumab for primary and peritoneal metastasis after hepatocellular carcinoma rupture. Anticancer Res. 2023;43(2):943\u20137.","journal-title":"Anticancer Res"},{"issue":"2","key":"2265_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12328-023-01895-7","volume":"17","author":"S Sato","year":"2024","unstructured":"Sato S, Aoki T, Matsumoto T, et al. Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review. Clin J Gastroenterol. 2024;17(2):292\u20139.","journal-title":"Clin J Gastroenterol"},{"issue":"1","key":"2265_CR26","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1186\/s12885-019-6287-8","volume":"19","author":"Z Liu","year":"2019","unstructured":"Liu Z, Li X, He X, et al. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report. BMC Cancer. 2019;19(1):1062.","journal-title":"BMC Cancer"},{"issue":"1\u20132","key":"2265_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000529405","volume":"40","author":"K Kurashiki","year":"2023","unstructured":"Kurashiki K, Soyama A, Hara T, et al. Pathologic complete response after chemotherapy with atezolizumab plus bevacizumab for hepatocellular carcinoma with tumor thrombus in the main portal trunk. Dig Surg. 2023;40(1\u20132):84\u20139.","journal-title":"Dig Surg"},{"issue":"3","key":"2265_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00535-024-02185-w","volume":"60","author":"R Miura","year":"2025","unstructured":"Miura R, Ono A, Nakahara H, et al. Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. J Gastroenterol. 2025;60(3):328\u201339.","journal-title":"J Gastroenterol"},{"issue":"6","key":"2265_CR29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00535-023-01985-w","volume":"58","author":"R Yamauchi","year":"2023","unstructured":"Yamauchi R, Ito T, Yoshio S, et al. Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. J Gastroenterol. 2023;58(6):565\u201374.","journal-title":"J Gastroenterol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02265-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-025-02265-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02265-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:45:05Z","timestamp":1771663505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-025-02265-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2265"],"URL":"https:\/\/doi.org\/10.1007\/s12328-025-02265-1","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}